The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer

Respiratory Care Clinics of North America

Volumn 9, Issue 2, 2003, Pages 207-236

  Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PRINOMASTAT; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ACUTE DISEASE; ADVANCED CANCER; ASTHENIA; BONE MARROW SUPPRESSION; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSIMETRY; DRUG MECHANISM; DRUG TARGETING; ELDERLY CARE; ESOPHAGITIS; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; RASH; REVIEW; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING; VOMITING;

EID: 0037529167     PISSN: 10785337     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5337(02)00089-8     Document Type: Review

References (113)

1. Greenlee R, Hill-Harmon M, Murray T, et al. Cancer statistics. CA Cancer J Clin 2001;51:15-36.
2. Bunn PJ, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;5:1087-100.
3. Arriagada R, Le Chevalier T, Quoix E. ASTRO Plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 1994;20:537-44.
4. Jeremic B, Shibamoto Y, Acimovic L. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-70.
5. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326:524-30.
6. Blanke C, Ansari C, Mantravadi R. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer. J Clin Oncol 1995;13:1425-9.
7. Brodin O, Nou E. Patients with non-resectable squamous cell carcinoma of the lung: a prospective, randomized study. Lung Cancer 1991;75:165.
8. Cullen M, Billingham L, Woodroffe C. Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-94.
9. Dillman R, Herndon J, Seagren S. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5.
10. Jeremic B, Shibamoto Y, Acimovic L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 1995;15:452-8.
11. Le Chevalier T, Arrigada R, Quoix E. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-23.
12. Mattson K, Holsti L, Holsti P. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988;24:477-82.
13. Miller L, Crowley J, Mira J. A randomized trial of chemotherapy and radiotherapy for stage III non-small cell lung cancer. Cancer Therapeutics 1998;1:229-36.
14. Sause W, Scott C, Taylor S. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
15. Trovo M, Minatel E, Franchin G. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24:11-5.
16. Sause W, Kolesar P, Taylor S. Five-year results: phase III trial of regionally advanced unresectable non-small cell lung cancer, RTOG 8808, ECOG 4588, SWOG 8992 [abstract]. Proc ASCO 1998;17:453a.
17. Tannock I. Treatment of cancer with radiation and drugs. J Clin Oncol 1996;14: 3156-74.
18. Mountain C. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
19. Curran WJ, Stafford P. Lack of apparent difference in outcome between clinically staged IIIA and IIIB non-small cell lung cancer treated with radiation therapy. J Clin Oncol 1990;8:409 15.
20. Reinfuss M, Skolyszewski J, Kowalska T. Palliative radiotherapy in asymptomatic patients with locally advanced, unresectable, non-small cell lung cancer. Stranhlenther Onkol 1993;169:709-15.
21. Komaki R, Scott C, Sause W. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88 08/ECOG 4588. Int J Radiat Oncol Biol Phys 1997;39:537-44.
22. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stage IIIa and IIIb non-small cell lung cancer: a meta-analysis. Cancer 1995;76:593-601.
23. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
24. Pritchard R, Anthony S. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer. Ann Intern Med 1996;125:723-9.
25. Furuse K. for the West Japan Lung Cancer Group. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692-9.
26. Curran WJ, Scott C, Langer C. Phase III comparison of sequential vs concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410 [abstract]. Proc ASCO 2000;9:484a.
27. Pierre F, Maurice P, Gilles R, et al. A randomized phase III trial of sequential chemoradiotherapy versus concurrent chemo-radiotherapy in locally advanced non-small cell lung cancer (NSCLC) (GLTO-GFPC NPC 95-01 study) [abstract]. Proc Am Soc Clin Oncol 2001;20:312.
28. Zatloukal P, Petruzelka L, Zemanova M. Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer: a randomized phase II study [abstract]. Proc Am Soc Clin Oncol 2002;21:290a.
29. Antonadau D, Coliarakis N, Synodinou M, et al. Randomized phase III trial of radiation treatment ± amisfostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 2001;51:915-22.
30. Rosenman J, Halle J, Socinski MA, et al. High-dose conformal radiation therapy for treatment of stage IIIA/IIIB non-small cell lung cancer: technical issues and results of a phase I/II trial. Internat J Rad Oncol. Biology and Physics; 2002;54:348-56.
31. Choy H, Curran WJ, Scott C, et al. Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (NA-NSCLC) [abstract]. Proc Am Soc Clin Oncol 2002;21:291a.
32. Langer C. Emerging role of new agents in the treatment of locally advanced non-small cell lung cancer (LA-NSCLC). Lung Cancer 2001;34(Suppl 1):S17-20.
33. Vokes E, Leopold K, Herndon J, et al. CALGB study 9431: a randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer 2000;29(Suppl 1):49.
34. Gaspar L, Gandara D, Chansky K, et al. Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb non-small cell lung cancer (NSCLC) (SWOG 9504): patterns of failure and updated survival [abstract]. Proc Am Soc Clin Oncol 2001;20:315.
35. Fossella F, Devore R, Kerr R, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-60.
36. Fossella F, Lee J, Murphy W. Phase II trial of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 1994;12:1232-7.
37. Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
38. Socinski MA, Rosenman JG, Halle J, et al. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B non-small cell lung cancer: a modified phase I trial. Cancer 2000;89:534-42.
39. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B non-small cell lung carcinoma: a modified phase I/II trial. Cancer 2001;92:1213-23.
40. Socinski MA, Rosenman JG, Halle J, et al. Induction carboplatin (C), irinotecan (I) and paclitaxel (P) followed by concurrent CP and dose-escalated thoracic conformal radiation therapy (TCRT) in stage IIIA/B non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2001;21:317a.
41. Finkelstein D, Ettinger D, Ruckdeschel J. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1986; 4:702-9.
42. Socinski M. Chemotherapy for stage IV non-small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, et al, editors. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia: WB Saunders; 2001. p. 307-25.
43. Anderson H, Hopwood R, Stephens R. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. Br J Cancer 2000;83:447-53.
44. Buccheri G, Ferrigno D, Rosso A. Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer. Lung Cancer 1990;6:87-98.
45. Cartei G, Cartei F, Canotne A. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small cell lung cancer. J Natl Cancer Inst 1993;85:794-800.
46. Cellerino R, Tummarello D, Guidi F. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J Clin Oncol 1991;9:1453-61.
47. Cormier Y, Bergeron D, La Forge J. Benefits of polychemotherapy in advanced non-small cell bronchogenic carcinoma. Cancer 1982;50:845-9.
48. Crawford J, O'Rourke M, Schiller J. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J Clin Oncol 1996;14:2774-84.
49. Ganz P, Figlin R, Haskell C. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Cancer 1989;63:1271-8.
50. Helsing M, Bergman B, Thaning L. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicenter randomized phase III trial. Eur J Cancer 1998;34:1036-44.
51. Kaasa S, Lund E, Thorud E. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 1991;67:2443-7.
52. Quoix E, Dietemann A, Charbonneau J. La chimiotherapie comportant du cisplatine est elle utile dans le cancer bronchique non microcellulaire au stade IV? Resultats d'une etude randomisee. Bull Cancer 1991;78:341-6 [in French].
53. Ranson M, Davidson N, Nicolson M. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2000;92:1074-80.
54. Rapp E, Pater J, Willan A. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633-41.
55. Roszkowski K, Pluzanska A, Krzakowski M. A multicenter, randomized phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27:145-57.
56. Stephens R, Fairlamb N, Gower N, et al. The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting [abstract]. Proc Am Soc Clin Oncol 2002;21:291a.
57. The Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival in elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
58. Thongprasert S, Sanuganmitra P, Juthapan N. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999;24:17-24.
59. Woods R, Williams C, Levi J. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990;61:608-11.
60. Donnadieu N, Paesmans M, Sculier J-P. Chemotherapy of non-small cell lung cancer according of disease extent: a meta-analysis of the literature. Lung Cancer 1991;7:243-52.
61. Grilli R, Oxman A, Julian J. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1860-72.
62. Marino P, Pampallona S, Preatoni A. Chemotherapy vs supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest 1994;106:861-5.
63. Cullen M, Joshi R, Chetiyawardana A. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 1998;58:359-61.
64. Ellis P, Smith I, Hardy J, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 1995;71:366-70.
65. Fernandez C, Rosell R, Abad-Esteve A. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 1989;28:29-33.
66. Hardy J, Noble T, Smith I. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 1989;60:764-6.
67. Osoba D, Rusthoven J, Turnbull K. Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small cell lung cancer. J Clin Oncol 1985; 3:1478 85.
68. Thatcher N, Anderson H, Betticher D. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumor-related symptoms. Anticancer Drugs 1995;6(Suppl 6):39-48.
69. Tummarello D, Graziano F, Isidori P, et al. Symptomatic, stage IV, non-small cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol 1995;35:249-53.
70. Breathnach O, Freidlin B, Conley B. Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol 2001;19:1734-42.
71. Baggstrom M, Socinski M, Hensing T, et al. Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol 2002;21:306a.
72. Aberola V, Camps C, Provencia M, et al. Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer (NSCLC): results of a Spanish Lung Cancer Group phase III trial (GEPC/98-02) [abstract]. Proc Am Soc Clin Oncol 2001;20:308a.
73. Kelly K, Crowley J, Bunn P, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
74. Rodriguez J, Pawel J, Pluzanska A, et al. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2001;20:314a.
75. Scagliotti G, De Marinis F, Finaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2001;20:308a.
76. Schiller J, Harrington D, Belani C. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
77. Van Meerbeeck J, Sarit E, Lianes P, et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2001;20:308a.
78. Chen Y, Perng R, Lee Y, et al. A phase II randomized trial of paclitaxel plus carboplatin (PC) or paclitaxel plus gemcitabine (PG) in inoperable, cemonaive non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2001;20:340a.
79. Georgoulias V, Papadakis E, Alexopoulos A. Platinum-based and non-platinum based chemotherapy in advanced non-small lung cancer: a randomized multicenter trial. Lancet 2001;357:1478-84.
80. Kosmidis P. Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small cell lung cancer. Oncology 2000;14(7)(Suppl 4): 41-8.
81. Georgoulias V, Ardavanis A, Agelidou M, et al. Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2002;21:291a.
82. Lilenbaum R, Herndon J, List M, et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, qualify of life (QoL), and cost-effectiveness [abstract]. Proc Am Soc Clin Oncol 2002;21:1a.
83. Sederholm C. Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG) [abstract]. Proc Am Soc Clin Oncol 2002;21:291a.
84. Fry W, Menek H, Winchester D. The National Cancer Dane Bone report on lung cancer. Cancer 1996;77:1947-55.
85. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2000; 18:2529-36.
86. Gridelli G, Perrone F, Cigolari S, et al. The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: gemcitabine + vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients (abstract]. Proc Am Soc Clin Oncol 2001;20:308a.
87. Hensing T, Socinski MA, Schell MA, et al. Age does not alter toxicity of survival for patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) treated with carboplatin (C) and paclitaxel (P) [abstract]. Proc Am Soc Clin Oncol 2001;20:346a.
88. Kelly K, Giarritta S, Hayes S, et al. Should older patients (Pts) receive combination chemotherapy for advanced non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308 [abstract]. Proc Am Soc Clin Oncol 2001;20:329a.
89. Langer C, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-81.
90. Kim K, Bonomi P, Kargler J. Two-year survival and prognostic factors for overall survival in advanced NSCLC: an ECOG experience. Proc Am Soc Clin Oncol 1998;17:461a.
91. Crino L, Norello S, Migliorino M. A phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer (NSCLC): Impact of PS = 2 vs 0 or 1 and age ≥ 70 vs ≤ 70 on chemotherapy outcome [abstract]. Proc Am Soc Clin Oncol 2002;21:315a.
92. DePierre A, Quoix E, Mercier M, et al. Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): a randomized study of vinorelbine (V) versus observation (OB) in patients (Pts) responding to induction therapy (French Cooperative Oncology Group) [abstract]. Proc Am Soc Clin Oncol 2001;20:309a.
93. Smith I, O'Brien M, Talbot D. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-43.
94. Socinski MA, Schell M, Peterman A, et al. A phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage IIIB/IV non-small cell lung cancer. J Clin Oncol 2002;20:1335-43.
95. Socinski MA, Schell M, Bakri K, et al. Second-line low-dose weekly paclitaxel in patients with stage IIIB/IV non-small cell lung cancer failing first-line carboplatin/paclitaxel. Cancer 2002;95:1265-73.
96. Huisman C, Smit E, Giaccone G. Second-line chemotherapy in relapsing or refractory non-small cell lung cancer: a review. J Clin Oncol 2000;18:3722 30.
97. Dancey J, Shepherd F, Ramlau R, et al. Quality of life (QoL) assessment in randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum-based chemotherapy [abstract]. Proc Am Soc Clin Oncol 1999;18:491a.
98. Crino L, Mosconi A, Scagliott IG, et al. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 1999;17:2081-5.
99. Gillenwater H, Tynan M, Natoli S, et al. Second-line gemcitabine in refractory stage IV non-small cell lung cancer: a phase II trial. Clin Lung Cancer 2000;2:133-8.
100. Hanahan D, Weinberg R. The hallmarks of cancer. Cell 2000;100:57-70.
101. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 2001;18(18S):41S-4.
102. Arteaga C. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19(18S):32S-40.
103. Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small cell lung cancer (IDEAL-1) [abstract]. Proc Am Soc Clin Oncol 2002;21:298a.
104. Kris M, Natale R, Herbst R, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL-2) [abstract]. Proc Am Soc Clin Oncol 2002;21:292a.
105. Perez-Soler R, Chachona A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2001;20:310a.
106. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002;29(Suppl 4):78-86.
107. Bissett D, O'Byrne K, von Pawel J, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2002;21:296a.
108. Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor priomastast in patients having advanced non-small cell lung cancer (NCSLC) [abstract]. Proc Am Soc Clin Oncol 2001;20:307a.
109. Shepherd F, Giaccone G, Debruque C, et al. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCIC-CTG and EORTC study [abstract]. Proc Am Soc Clin Oncol 2001;20:4a.
110. Swannie H, Kaye S. Protein inase C inhibitors. Current Oncology Reports 2002;4(1): 37-46.
111. Yuen A, Halsey J, Fisher G, et al. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-Alpha, with carboplatin and paclitaxel in non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2001;20:309a.
112. Galligioni E, Ferro A. Angiogenesis and antiangiogenic agents in non-small cell lung cancer. Lung Cancer 2001;34(Suppl 4):S3-7.
113. Johnson D, DeVore R, Kabbinavar F, et al. Carboplatin (C) + paclitaxel (P) + RhuMab-FEGF (AVF) may prolong survival in advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2001;20:315a.